title: Chloroquine use improves dengue-related symptoms.
abstract: Dengue is the most important arboviral disease in the world. As chloroquine, an antimalarial agent, has shown some antiviral effects, this study evaluated its effect in patients with dengue. A randomised, double-blind study was performed by administering chloroquine or placebo for three days to 129 patients with dengue-related symptoms. Of these patients, 37 were confirmed as having dengue and completed the study; in total, 19 dengue patients received chloroquine and 18 received placebo. There was no significant difference in the duration of the disease or the degree and days of fever. However, 12 patients (63%) with confirmed dengue reported a substantial decrease in pain intensity and a great improvement in their ability to perform daily activities (p = 0.0004) while on the medication and the symptoms returned immediately after these patients stopped taking the medication. The same effect was not observed in patients with diseases other than dengue. Therefore, this study shows that patients with dengue treated with chloroquine had an improvement in their quality of life and were able to resume their daily activities. However, as chloroquine did not alter the duration of the disease or the intensity and days of fever, further studies are necessary to confirm the clinical effects and to assess the side effects of chloroquine in dengue patients.
authors.affiliation: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brasil.
authors.forename: Marcos Carvalho
authors.initials: MC
authors.lastname: Borges
authors.forename: Luiza Antunes
authors.initials: LA
authors.lastname: Castro
authors.forename: Benedito Antonio Lopes de
authors.initials: BA
authors.lastname: Fonseca
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D002738:Chloroquine / Q000627:therapeutic use*; D003715:Dengue / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D059408:Pain Management / Q000379:methods; D011788:Quality of Life; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D002738:Chloroquine
references.citation: J Clin Microbiol. 1992 Mar;30(3):545-51
references.pmid: 1372617
references.citation: Antiviral Res. 2010 Mar;85(3):450-62
references.pmid: 20060421
references.citation: Am J Trop Med Hyg. 1989 Apr;40(4):418-27
references.pmid: 2540664
references.citation: Antimicrob Agents Chemother. 2009 Aug;53(8):3416-21
references.pmid: 19506054
references.citation: World Health Stat Q. 1997;50(3-4):161-9
references.pmid: 9477544
references.citation: Antimicrob Agents Chemother. 2010 Feb;54(2):871-81
references.pmid: 19949061
references.citation: Arch Virol. 2007;152(12):2217-24
references.pmid: 17891330
references.citation: Adv Virus Res. 2003;59:23-61
references.pmid: 14696326
references.citation: Virology. 1990 Feb;174(2):450-8
references.pmid: 2154882
references.citation: PLoS Negl Trop Dis. 2010 Aug 10;4(8):e785
references.pmid: 20706626
references.citation: Mem Inst Oswaldo Cruz. 1999 May-Jun;94(3):387-94
references.pmid: 10348988
references.citation: Am J Trop Med Hyg. 1993 Mar;48(3):324-31
references.pmid: 8470771
references.citation: Int J Antimicrob Agents. 2007 Oct;30(4):297-308
references.pmid: 17629679
references.citation: Drug Saf. 2004;27(1):25-61
references.pmid: 14720085
references.citation: Invest Clin. 2008 Jun;49(2):135-8
references.pmid: 18717261
references.citation: Rev Clin Esp. 2005 May;205(5):230-2
references.pmid: 15970155
references.citation: Mem Inst Oswaldo Cruz. 2000;95 Suppl 1:179-81
references.pmid: 11142711
references.citation: Chemotherapy. 2007;53(6):385-91
references.pmid: 17934257
references.citation: Virol J. 2005 Aug 22;2:69
references.pmid: 16115318
references.citation: J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):223-32
references.pmid: 15076236
references.citation: Virol J. 2007 May 03;4:39
references.pmid: 17477867
references.citation: J Med Virol. 2010 Aug;82(8):1400-5
references.pmid: 20578057
references.citation: Mem Inst Oswaldo Cruz. 2011 Aug;106(5):594-605
references.pmid: 21894381
references.citation: Lancet Infect Dis. 2003 Nov;3(11):722-7
references.pmid: 14592603
references.citation: Clin Vaccine Immunol. 2006 Nov;13(11):1185-9
references.pmid: 16988003
references.citation: Lancet Infect Dis. 2006 Feb;6(2):67-9
references.pmid: 16439323